This trial is active, not recruiting.

Conditions sleep apnea, central, sleep disordered breathing, heart failure
Treatments treatment group (transvenous stimulation of the phrenic nerve), control group (optimal medical therapy)
Sponsor Respicardia, Inc.
Start date March 2013
End date October 2016
Trial size 173 participants
Trial identifier NCT01816776, Respicardia CR-1005


The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remedē® systems.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
treatment group (transvenous stimulation of the phrenic nerve) remedē System
device implant, optimal medical therapy and device initiation 1 month post implant.
Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
control group (optimal medical therapy) Optimal Medical Therapy
device implant, optimal medical therapy and delayed device initiation (7 months post device implant)

Primary Outcomes

Apnea-hypopnea index (AHI)
time frame: 6 months
Primary Safety Endpoint
time frame: 12 months

Secondary Outcomes

Central Apnea Index (CAI)
time frame: 6 months
Apnea Hypopnea Index (AHI)
time frame: 6 months
Arousal Index (ArI)
time frame: 6 months
Rapid eye movement sleep (REM)
time frame: 6 months
Patient Global Assessment (PGA)
time frame: 6 months
Oxygen desaturation index (ODI4)
time frame: 6 months
Epworth Sleepiness Scale (ESS)
time frame: 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. At least 18 years of age 2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of scheduled implant: - Apnea/Hypopnea Index (AHI) greater than or equal to 20; - Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central apnea events; - Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI 3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no hospitalizations for illness, no breathing mask-based therapy, and on stable medications and therapies: - Stable medications are defined as no changes during this period except for those within a pre-specified sliding scale medication regimen; - If the subject has heart failure, the baseline testing (including PSG) should occur at least 6 months after initial diagnosis; - If the subject has systolic heart failure, the baseline testing (including PSG) should occur after maximally titrating beta blockers, ACE-I and other medications indicated in the current guidelines (unless contraindicated or not considered medically necessary) and after receiving any indicated device therapy including devices for cardiac resynchronization therapy and/or primary prevention of sudden cardiac death; - If subject has a hospitalization or physician visit requiring IV medication between the screening PSG and implant, the subject must be re-screened when stable 4. Expected to tolerate study procedures in the opinion of the investigator, in particular: - Ability to lie down long enough to insert the remede system without shortness of breath and able to tolerate instrumentation for the Polysomnogram/Polygram testing; - Expected to tolerate therapy titration and the sensation of therapy, and communicate therapy experience. 5. In the investigator's opinion, willing and able to comply with all study requirements 6. Signed the Institutional Revew Board/Medical Ethics Committee approved informed consent (HIPAA authorization in the U.S.) Exclusion Criteria: 1. Pacemaker dependent subjects without any physiologic escape rhythm 2. Suspected inability to place catheter for delivery of stimulation lead (e.g. previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.) 3. Evidence of phrenic nerve palsy 4. More than 2 previous open chest surgical procedures (e.g., CABG) 5. Etiology of central sleep apnea known to be caused primarily by pain medication 6. Documented history of psychosis or severe bipolar disorder 7. Cerebrovascular accident (CVA) within 12 months of baseline testing 8. History of idiopathic pulmonary hypertension, World Health Organization Class 1 9. Limited pulmonary function with either FEV1/FVC less than 65% of predicted value or FVC less than 60% of predicted value 10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes of quiet rest 11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6 months post therapy initiation visit 12. Active infection or sepsis within 30 days of enrollment 13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault equation 14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab normals at each site) 15. Hemoglobin less than 8 gm/dL 16. In subjects with heart failure, ACC/AHA Heart Stage D 17. Within the 3 months prior to baseline testing, any of the following: uncorrected severe valvular stenosis, valve replacement or repair (percutaneous or surgical), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, percutaneous coronary intervention (PCI), cardiac ablation, new cardiac resynchronization device or new pacemaker implant 18. New implantable cardioverter defibrillator or any implantable device generator change-out within 30 days prior to baseline testing or anticipated within the first 6 months of enrollment 19. Other anticipated surgery or invasive procedure expected to affect ability to perform testing at 6-month post-therapy initiation visit 20. Unstable angina 21. Allergy to or intolerant of contrast dye 22. Pregnancy or of child bearing potential without a negative pregnancy test within 10 days prior to remede system implant 23. Life expectancy or expected time to transplant or left ventricular assist device of less than 12 months 24. Currently enrolled or planning to enroll in another study that may conflict with protocol requirements or confound subject results in this trial

Additional Information

Official title A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea
Principal investigator Maria Rosa Costanzo, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Respicardia, Inc..